Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 7/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035827 | 0.94 | MAPK8 (0.35) | MAPK8JAK2JAK1TYK2JAK3 | |
| SCHEMBL15041191 | 0.80 | MAPK8 (0.40) | MAPK8MAPK14 | |
| SCHEMBL15041203 | 0.77 | MAPK8 (0.43) | MAPK8MAPK14 | |
| SCHEMBL15041428 | 0.77 | MAPK14 (0.43) | MAPK8MAPK14JAK2JAK1TYK2 | |
| SCHEMBL15041749 | 0.77 | MAPK8 (0.42) | MAPK8MAPK14CAMK2D | |
| SCHEMBL15041364 | 0.74 | MAPK8 (0.39) | MAPK8MAPK14 | |
| SCHEMBL15034951 | 0.74 | CDK4 (0.37) | MAPK8JAK2JAK1TYK2JAK3 | |
| SCHEMBL15041376 | 0.74 | MAPK14 (0.36) | MAPK8MAPK14 | |
| SCHEMBL15035858 | 0.72 | CDK4 (0.38) | — | |
| SCHEMBL15041580 | 0.71 | MAPK8 (0.43) | MAPK8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | MAPK8 493/4885MAPK14 382/4885JAK2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.